Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
BicycleTx Limited
Maastricht University Medical Center
Incyte Corporation
Toray Industries, Inc
Eli Lilly and Company
Sumitomo Pharma America, Inc.
Incyte Corporation
Duke University
Five Prime Therapeutics, Inc.